Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-05-11

Clinical Trial Update: Ivermectin Nasal Drops in Post COVID-19 Parosmia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ivermectin nasal drops for post-COVID-19 parosmia is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ivermectin nasal drops (ivermectin)

Snippet

Sponsor: Menoufia University | Conditions: Parosmia | Phase 2 | Status: UNKNOWN